Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide Mesylate (LMIS 50 mg) in Advanced Prostate Carcinoma
NCT02234115Phase 3Completed
- Sponsor
- Foresee Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Aug 2016
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of leuprolide in prostate carcinoma, sponsored by Foresee Pharmaceuticals. Started Aug 2014; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate carcinoma
Beyond the preview
Go deeper on NCT02234115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234115.